MOLECULIN BIOTECH INC (MBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.46+1.93%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · MBRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -15.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
MBRX — capital allocation — Material Modifications of Rights of Security Holders
Dated 2026-10-20
Material Modifications of Rights of Security Holders. To the extent required by
Why it matters: Nasdaq told Moleculin its share price had stayed below the $1.00 listing level. A listing update may affect access to trading.
Worry ifA company filing reports Nasdaq has started to delist the shares, or they no longer trade on Nasdaq.
Less concerning ifA company filing says Nasdaq withdrew the notice or the company met the listing rule.
Why it matters: The company said its cash would fund planned work into Q1 2027. It also said more funding is needed for its trials.
Worry ifA filing or company release reports new financing before Q1 2027. The funds are available for planned clinical trials.
Less concerning ifThe company reports no new financing by the end of Q1 2027, or says trial work is delayed for lack of funds.
Why it matters: The full Part A results are meant to guide the dose for Part B. A timely start would mark the next step in the pivotal trial.
Supportive ifMoleculin names a Part B dose and reports that Part B has started by the end of Q2 2027.
Worry ifMoleculin has not named a Part B dose or has not started Part B by the end of Q2 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$495 on $10,000 · ±4.9% | How much price usually moves either way. |
| Bad day | $1,161 loss on $10,000 · 11.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,787 loss on $10,000 · 97.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.